13 High Growth Large Cap Stocks To Invest In

Page 2 of 11

10. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Number of Hedge Fund Holders: 68

Average 5-Year Revenue Growth: 25.83%

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotech company dedicated to developing treatments for cystic fibrosis and other serious diseases. On March 7, 2025, the company received approval from the UK’s Medicines and Healthcare products Regulatory Agency for ALYFTREK, a once-daily treatment for cystic fibrosis in patients aged six and older with specific genetic mutations. The company is collaborating with NICE and the NHS to ensure swift access for eligible patients. ALYFTREK was previously approved in the United States in December 2024, and Vertex is in the process of securing approvals in Europe, Canada, Switzerland, Australia, and New Zealand. It is one of the top high growth stocks to monitor.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) had a strong fourth quarter, bringing in $2.91 billion in revenue, a 16% jump from last year. For all of 2024, revenue exceeded $11 billion and beat Wall Street expectations. Looking ahead to 2025, the company is focused on expanding patient access to its treatments, including the newly launched CASGEVY and two recently approved US drugs – ALYFTREK for cystic fibrosis and JOURNAVX, the first non-opioid pain medication of its kind in over 20 years. Vertex ended the year with $11.2 billion in cash and investments, continuing to prioritize innovation and stock buybacks, repurchasing 2.7 million shares in 2024.

According to Insider Monkey’s fourth quarter database, 68 hedge funds were long Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), compared to 55 funds in the last quarter.

Page 2 of 11